FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/10/095535 [Registered on: 01/10/2025] Trial Registered Prospectively
Last Modified On: 30/09/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Quasi Experimental Study]  
Study Design  Other 
Public Title of Study   Impact of Nurse-Led Lifestyle Modification on Recovery After Angioplasty in Patients With Complex Heart Disease 
Scientific Title of Study   Effect of nurse-led lifestyle modification program on short term clinical outcomes in patients with higher SYNTAX score undergoing PCI: A quasi experimental study.  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Vandana Devi 
Designation  PG student 
Affiliation  AIIMS,Jodhpur 
Address  Room No. 108,College of Nursing AIIMS Jodhpur, Industrial area,2nd phase,Basni,Jodhpur, Rajasthan.

Jodhpur
RAJASTHAN
342005
India 
Phone  7355099230  
Fax    
Email  vandanayadav7355@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Nipin Kalal 
Designation  Assistant Professor 
Affiliation  AIIMS,Jodhpur 
Address  ROOM no. 107,First floor, College Of Nursing AIIMS, Jodhpur,Industrial area,2nd phase,Basni,Jodhpur, Rajasthan

Jodhpur
RAJASTHAN
342005
India 
Phone  918955945598  
Fax    
Email  kalalnipin@gmail.com   
 
Details of Contact Person
Public Query
 
Name  Nipin Kalal 
Designation  Assistant Professor 
Affiliation  AIIMS,Jodhpur 
Address  Room no.-107,First floor, College Of Nursing AIIMS, Jodhpur, Industrial area,2nd phase,Basni,Jodhpur, Rjasthan

Jodhpur
RAJASTHAN
342005
India 
Phone  918955945598  
Fax    
Email  kalalnipin@gmail.com   
 
Source of Monetary or Material Support  
All India institute of Medical Science, Jodhpur, marudar hi industrial area second phase, Basni, Jodhpur, Rajasthan 342005, INDIA. 
 
Primary Sponsor  
Name  NOT APPLICABLE 
Address  N/A 
Type of Sponsor  Other [Not applicable] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Vandana Devi  AIIMS Jodhpur  Room No. 427, 4TH Floor, AIIMS JODHPUR, Industrial area,2nd Phase,Basni,Jodhpur Rajasthan
Jodhpur
RAJASTHAN 
07355099230

vandanayadav7355@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethical committee, AIIMS JODHPUR  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: I739||Peripheral vascular disease, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Routine care  The control group will receive standard routine care by Nurse. 
Intervention  The experimental group will receive nurse-led lifestyle modification program  The experimental group will receive a nurse-led lifestyle modification program in addition to the standard treatment. The duration of intervention will be of 1 month. The intervention will consist of three components. First, individualized counseling sessions will be conducted on the day of discharge for the patients and their family members. Each session will last for about 15–20 minutes and will focus on providing health education regarding coronary artery disease, possible post-PCI complications, and lifestyle modifications such as dietary changes, physical activity, smoking and alcohol cessation, stress management, and medication adherence to prevent further complications. Second, a patient information booklet, developed based on these components, will be distributed to the participants at the time of discharge for their reference and reinforcement. Third, telephonic follow-up and reinforcement will be provided on a weekly basis for one month to ensure compliance with the interventions and to address any queries or difficulties faced by the participants. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  75.00 Year(s)
Gender  Both 
Details  Participants included in the study will be those who have undergone percutaneous coronary intervention (PCI) and are willing to participate, are above 18 years of age, can understand either Hindi or English, are accessible via telephone, and have a SYNTAX score of 22 or higher. 
 
ExclusionCriteria 
Details  Patient who needs emergency cardiac surgery post PCI.
Patient who are admitted for MACE and going for PCI.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Primary CLINICAL OUTCOMES
PART-1: MACE check list
Myocardial infarction (MI), stroke/cerebrovascular event, hospital readmission, revascularization, cardiovascular death and mortality (all-cause)
PART-2: Novel haematological indices
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), monocyte-to-HDL ratio (MHR), high-sensitivity C-reactive protein (hs-CRP), NT-Pro (BNP), and the triglyceride-glucose (TyG) Index.
 
Every week for 1 month  
 
Secondary Outcome  
Outcome  TimePoints 
Secondary outcomes
Ejection fraction & blood pressure
 
At baseline & after 1 month. 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   24/10/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Clinical Study Report

  3. Who will be able to view these files?
    Response - Researchers who provide a methodologically sound proposal.

  4. For what types of analyses will this data be available?
    Response - Any purpose.

  5. By what mechanism will data be made available?
    Response (Others) - 

  6. For how long will this data be available start date provided 02-07-2026 and end date provided 02-11-2031?
    Response - Beginning 3 months and ending 5 years following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, contributing to approximately 17.9 million deaths annually, with nearly 85 percent due to heart attacks and strokes. The burden is particularly high in low and middle income countries due to disparities in healthcare access, lifestyle related risk factors, and socioeconomic conditions. Coronary artery disease (CAD), a major type of CVD, occurs when fatty deposits build up in the coronary arteries, restricting blood flow and increasing the risk of heart attacks. Percutaneous coronary intervention (PCI) is a common minimally invasive procedure used to treat CAD, usually through balloon angioplasty or stent placement, but complications such as restenosis, recurrent myocardial infarction, and need for repeat procedures remain. The SYNTAX score is a widely used tool to assess CAD complexity and guide revascularization strategies.

In India, the prevalence of CVD is rising in both urban and rural areas. Patients with higher SYNTAX scores (22 or above) have more complex CAD and face increased risks of adverse events post PCI, including cardiogenic shock, cardiac arrest, stroke, and restenosis. Hematological indices such as neutrophil to lymphocyte ratio, monocyte to lymphocyte ratio, platelet to lymphocyte ratio, systemic immune inflammation index, and systemic inflammation response index have been identified as cost effective prognostic markers for major adverse cardiac events after PCI. Secondary prevention, including adherence to medical therapy and lifestyle modifications like diet, physical activity, smoking cessation, stress management, and medication adherence, reduces complications and improves outcomes. However, patients often face challenges in sustaining these practices without proper guidance. Nurse led lifestyle modification programs have shown effectiveness in improving adherence and recovery, but there is limited evidence regarding their role in patients with higher SYNTAX scores undergoing PCI.

The present study aims to evaluate the effect of a nurse led lifestyle modification program on short term clinical outcomes in patients with higher SYNTAX scores undergoing PCI. The intervention includes individualized health education on diet, exercise, smoking cessation, stress management, and medication adherence, along with distribution of an educational booklet and weekly telephonic follow ups for one month. Short term clinical outcomes will include the occurrence of major adverse cardiac events, changes in novel hematological indices, and secondary outcomes such as ejection fraction and blood pressure, measured after one month of PCI. A higher SYNTAX score will be defined as 22 or above.

The study objectives are to assess and compare short term clinical outcomes in the experimental and control groups, and to examine associations between selected demographic and clinical variables with short term outcomes. The hypotheses to be tested at the 0.05 level of significance are: (H01) there will be no significant difference in short term clinical outcomes between the experimental and control groups, and (H02) there will be no significant association between selected demographic and clinical variables and short term outcomes in both groups.


 
Close